Over the last few years the therapeutic approach to demyelinating diseases has radically changed, strategies having been developed aimed at partnering the classic symptomatic treatments with the most advanced regenerative medicine tools. At first, the transplantation of myelinogenic cells, Schwann cells or oligodendrocytes was suggested, but the considerable technical difficulties, (poor availability, difficulties in harvesting and culturing, and the problem of rejection in the event of non-autologous sources), shifted attention towards more versatile cellular types, such as Mesenchymal Stem Cells (MSCs). Recent studies have already demonstrate both in vitro and in vivo that glially-primed MSCs (through exposure to chemical cocktails) have myelogenic abilities. In spite of a large number of papers on glially-differentiated MSCs, little is known about the ability of undifferentiated MSCs to myelinate axons and processes. Here we have demonstrated that also undifferentiated MSCs have the ability to myelinate, since they induce the myelination of rat DRG neuron processes after direct co-culturing. In this process a pivotal role is performed by the p75 receptor.
Keywords: BDNF; Brain Derived Neurotrophic Factor; DRG; DRG neurons; Dorsal Root Ganglia; FUDR; Fluorodeoxyuridine; GFAP; Glial Fibrillary Acidic Protein; MAG; MBP; MSCs; Mesenchymal Stem Cells; Myelin; Myelin Associated Glicoprotein; Myelin Basic Protein; NGF; Nerve Growth Factor; PI; Propidium Iodide; p75.
© 2013 Published by Elsevier Inc.